Tyra Biosciences, Inc. (NASDAQ: TYRA) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Tyra Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $19.57, Tyra Biosciences, Inc. trades at 1.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -40.1%, return on invested capital of -26.1% and a free cash flow yield of -8.9%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 23.93. Over the past 52 weeks the share price ranged from $14.84 to $40.65, with a beta of 0.75.
Tyra Biosciences, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 7 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Tyra Biosciences, Inc. (TYRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 46.8% / 30% · Interest income / Revenue 376300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 46.8% / 33% · Receivables / Mkt Cap (36m) 0.15% / 49% · Interest income / Revenue 376300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 46.8% / 33.33% · Receivables / Mkt Cap (24m) 0.15% / 33.33% · Interest income / Revenue 376300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.64% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.8% / 33.33% · Receivables / Avg Assets (4Q) 0.12% / 33.33% · Interest income / Revenue 376300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.3% / 33.33% · (Cash+Recv) / Total Assets 96.6% / 33.33% · Interest income / Revenue 376300000.0% / 5% | Fail |
No. As of September 2026, Tyra Biosciences, Inc. (TYRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Tyra Biosciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 376300000.0% of each dividend: Tyra Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.